H.C. Wainwright initiated coverage of Satellos Bioscience with a Buy rating and C$1.20 price target. Satellos is a pre-clinical stage biotechnology company focused on developing novel treatment for degenerative muscle diseases, the analyst tells investors in a research note. The firm believes Satellos has the potential to become a disruptive muscle diseases company by leveraging its expertise in satellite cells and muscle regeneration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MSCLF: